

Neeraj Agarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7696248/publications.pdf>

Version: 2024-02-01

102
papers

7,382
citations

136950

32
h-index

58581

82
g-index

104
all docs

104
docs citations

104
times ranked

8396
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
2	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 13-24.	27.0	904
3	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	10.7	789
4	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
5	Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1136-1142.	1.6	268
6	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2098-2106.	1.6	264
7	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2474-2485.	1.6	250
8	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2294-2303.	1.6	218
9	Kidney Cancer, Version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 151-159.	4.9	198
10	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	7.0	193
11	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	4.1	189
12	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	1.6	127
13	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	10.7	124
14	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	7.4	122
15	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 557-564.	1.9	108
16	Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.	3.0	103
17	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	4.9	93
18	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2636-2643.	1.6	77

#	ARTICLE	IF	CITATIONS
19	Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncology Practice, 2022, 18, 45-55.	2.9	75
20	Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. Frontiers in Oncology, 2017, 7, 56.	2.8	73
21	Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer, 2018, 124, 3105-3117.	4.1	72
22	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
23	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1518-1530.	10.7	69
24	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Journal of Clinical Oncology, 2021, 39, 3725-3736.	1.6	69
25	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.	1.9	65
26	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. European Urology, 2020, 78, 652-656.	1.9	64
27	COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocrine-Related Cancer, 2020, 27, R281-R292.	3.1	64
28	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology, 2019, 3, 1-23.	3.0	63
29	PD-1 checkpoint inhibition: Toxicities and management. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 701-707.	1.6	57
30	Macrophage HIF-1 α Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research, 2020, 26, 4970-4982.	7.0	45
31	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1601-1608.	1.6	44
32	FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 2015, 15, 15.	2.8	35
33	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2546-2555.	7.0	33
34	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 2021, 26, e270-e278.	3.7	33
35	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. Journal of Urology, 2020, 204, 63-70.	0.4	32
36	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	1.9	31

#	ARTICLE	IF	CITATIONS
37	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	2.0	30
38	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. <i>Future Oncology</i> , 2022, 18, 425-436.	2.4	28
39	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). <i>Lancet Oncology</i> , The, 2022, 23, 899-909.	10.7	26
40	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 319-329.	3.8	20
41	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3017-3027.	7.0	19
42	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	3.7	19
43	Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). <i>Clinical Cancer Research</i> , 2021, 27, 1967-1973.	7.0	18
44	Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5074-5074.	1.6	18
45	Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 139-139.	1.6	18
46	Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5072-5072.	1.6	17
47	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	3.0	17
48	Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. <i>Current Treatment Options in Oncology</i> , 2019, 20, 14.	3.0	16
49	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	1.9	15
50	Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2896-2900.	4.1	15
51	Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. <i>Research and Reports in Urology</i> , 2018, Volume 10, 205-217.	1.0	15
52	<p>Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3741-3749.	1.9	15
53	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2104-2110.	7.0	15
54	Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 149-154.	1.0	14

#	ARTICLE	IF	CITATIONS
55	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). <i>Journal of Clinical Oncology</i> , 2022, 40, 3301-3309.	1.6	14
56	Stimulation by serum of the Na ⁺ /H ⁺ antiporter in quiescent pig kidney epithelial (LLC-PK1) cells and role of the antiporter in the reinitiation of DNA synthesis. <i>Journal of Cellular Physiology</i> , 1987, 132, 173-177.	4.1	13
57	Current Treatment Landscape of Advanced Papillary Renal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2981-2983.	1.6	13
58	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. <i>Oncologist</i> , 2021, 26, 1006-e2129.	3.7	13
59	PARP inhibitors in castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100199.	1.7	12
60	Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).. <i>Journal of Clinical Oncology</i> , 2020, 38, 82-82.	1.6	12
61	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. <i>Drugs</i> , 2021, 81, 191-206.	10.9	11
62	Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5076-5076.	1.6	11
63	Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5073-5073.	1.6	10
64	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 319-329.	3.8	10
65	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	2.4	10
66	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	1.9	10
67	Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 205-207.	1.0	9
68	Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. <i>JAMA Oncology</i> , 2017, 3, e170231.	7.1	9
69	Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 676-677.	1.6	9
70	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4807-4813.	7.0	9
71	Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. <i>Oncologist</i> , 2021, 26, 751-760.	3.7	9
72	Missense mutation of the last nucleotide of exon 1 (G→C) of globin gene not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild allele. <i>Haematologica</i> , 2007, 92, 1715-1716.	3.5	8

#	ARTICLE	IF	CITATIONS
73	Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Review of Anticancer Therapy, 2022, 22, 335-341.	2.4	8
74	Efficacy and safety exposureâ€“response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemotherapy and Pharmacology, 2022, 89, 629-641.	2.3	6
75	Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs and Aging, 2019, 36, 395-401.	2.7	5
76	Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 363-365.	3.9	5
77	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer and Prostatic Diseases, 2022, 25, 306-313.	3.9	5
78	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, TPS42-TPS42.	1.6	4
79	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncology, 2022, 18, 35-45.	2.4	4
80	First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 377-387.	5.4	4
81	Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. Oncologist, 2019, 24, 143-145.	3.7	3
82	Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 25, 100205.	1.7	3
83	Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axisâ€“Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. European Urology Focus, 2023, 9, 106-109.	3.1	3
84	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. Journal of Geriatric Oncology, 2020, 11, 724-726.	1.0	2
85	PARP Inhibitors in Prostate Cancer: A Promise Delivered. European Urology Oncology, 2020, 3, 612-614.	5.4	2
86	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2018, 36, 615-615.	1.6	2
87	An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, TPS403-TPS403.	1.6	2
88	Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy.. Journal of Clinical Oncology, 2018, 36, TPS528-TPS528.	1.6	2
89	Use and outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel in addition to androgen deprivation therapy (ADT): Analysis of real-world data in the United States (US).. Journal of Clinical Oncology, 2020, 38, e19322-e19322.	1.6	2
90	Reply to M.A.N. Åžendur et al and J. Michels. Journal of Clinical Oncology, 2017, 35, 123-123.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 186-188.	3.7	1
92	Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. <i>Oncologist</i> , 2021, 26, 904-905.	3.7	1
93	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 634-634.	1.6	1
94	Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. <i>European Urology Oncology</i> , 2021, 4, 553-557.	5.4	0
95	Drug development in metastatic prostate cancer: lessons from ACIS. <i>Lancet Oncology</i> , The, 2021, 22, 1487-1488.	10.7	0
96	Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 448-448.	1.6	0
97	Independent assessment of TP53 and PTEN as predictors of response to enzalutamide (ENZ) or abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 351-351.	1.6	0
98	Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 311-311.	1.6	0
99	Germline variant in HSD3B1 (1245 A>C) and response to abiraterone acetate plus prednisone (AA) in men with new onset metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 173-173.	1.6	0
100	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS541-TPS541.	1.6	0
101	Targeting bacteroides in the stool microbiome and response to treatment (Rx) with first-line VEGFTKI in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 584-584.	1.6	0
102	Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 314-314.	1.6	0